| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
New data reinforce Mirum's commitment to advancing therapies and improving the lives of patients across diverse rare liver ...
Cantor Fitzgerald analyst Josh Schimmer maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price...
Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the pri...
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises t...
Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2025 sales outlook from $490.000 million-$510.000 million to $500.000 million-$510...
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of...